B-lymfocytdepletring og andre biologiske behandlingsmuligheder ved Graves' oftalmopatiTumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease
Research output: Contribution to journal › Journal article › Research › peer-review
The current medical treatment options for Graves' ophthalmopathy (GO) are unsatisfactory. Recent treatment of GO patients with the B-lymphocyte depleting monoclonal antibody rituximab or with the anti-tumor necrosis factor-alpha agents etanercept and infliximab has shown promising results. We discuss the use of these and other biological agents targeting B lymphocytes, T-lymphocyte interaction with antigen-presenting cells, or cytokines in the future treatment of GO
Udgivelsesdato: 2008/6/9
Udgivelsesdato: 2008/6/9
| Original language | Danish |
|---|---|
| Journal | Ugeskrift for læger |
| Volume | 170 |
| Issue number | 24 |
| Pages (from-to) | 2128-2130 |
| Number of pages | 2 |
| ISSN | 0041-5782 |
| Publication status | Published - 2008 |
ID: 14148866